Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$63.22 +1.9%	$61.71	$43.70 ▼ $86.53	$2.01B	-1.5	46,625 shs	180,040 shs
HRMY Harmony Biosciences	$34.00 -1.0%	$33.59	$26.47 ▼ $41.61	$1.95B	0.83	634,908 shs	370,534 shs
IDYA IDEAYA Biosciences	$22.48 -1.4%	$20.54	$13.45 ▼ $44.42	$1.97B	0.03	993,697 shs	804,315 shs
PGEN Precigen	$1.83 -4.2%	$1.46	$0.65 ▼ $2.17	$540.18M	1.78	1.47 million shs	1.35 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	+5.83%	+1.74%	+11.70%	+26.95%
HRMY Harmony Biosciences	0.00%	+5.95%	+2.01%	+16.56%	+1.43%
IDYA IDEAYA Biosciences	0.00%	+1.77%	+0.90%	+34.21%	-39.76%
PGEN Precigen	0.00%	+12.62%	+20.39%	+30.71%	+18.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.3479 of 5 stars	3.5	2.0	0.0	3.1	0.8	0.6
HRMY Harmony Biosciences	4.8607 of 5 stars	4.5	1.0	0.0	4.0	3.3	4.4
IDYA IDEAYA Biosciences	3.6084 of 5 stars	3.4	1.0	4.4	2.1	1.7	0.0
PGEN Precigen	4.109 of 5 stars	3.5	0.0	4.7	4.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	52.91% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.33	50.98% Upside
IDYA IDEAYA Biosciences	2.85	Moderate Buy	$47.55	111.50% Upside
PGEN Precigen	3.00	Buy	$6.00	227.87% Upside

Current Analyst Ratings Breakdown

Latest PGEN, BLTE, IDYA, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$33.00
7/10/2025	IDYA IDEAYA Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$25.00
7/9/2025	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$57.00 ➝ $30.00
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.72 per share	N/A
HRMY Harmony Biosciences	$714.73M	2.73	$2.95 per share	11.54	$11.56 per share	2.94
IDYA IDEAYA Biosciences	$7M	281.26	N/A	N/A	$12.25 per share	1.84
PGEN Precigen	$3.92M	137.80	N/A	N/A	$0.13 per share	14.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.36	N/A	N/A	N/A	N/A	-32.07%	-30.91%	8/8/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	12.98	10.93	0.50	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)

Latest PGEN, BLTE, IDYA, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	BLTE Belite Bio	-$0.42	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	N/A	N/A	N/A	$3.48 million	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	24.31	24.31
HRMY Harmony Biosciences	0.22	3.67	3.63
IDYA IDEAYA Biosciences	N/A	13.92	13.92
PGEN Precigen	N/A	3.53	3.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
HRMY Harmony Biosciences	86.23%
IDYA IDEAYA Biosciences	98.29%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
HRMY Harmony Biosciences	23.60%
IDYA IDEAYA Biosciences	2.50%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable

PGEN, BLTE, IDYA, and HRMY Headlines

Recent News About These Companies

Precigen (NASDAQ:PGEN) Upgraded at Wall Street Zen

July 12 at 2:42 AM | marketbeat.com

Precigen (NASDAQ:PGEN) Sees Unusually-High Trading Volume - Should You Buy?

July 9, 2025 | marketbeat.com

Iridian Asset Management LLC CT Sells 656,113 Shares of Precigen, Inc. (NASDAQ:PGEN)

July 9, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Shares Up 6.6% - Time to Buy?

July 8, 2025 | marketbeat.com

Precigen: August Is Pivotal For This Biotech Innovator

July 7, 2025 | seekingalpha.com

Precigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Precigen (NASDAQ:PGEN) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?

July 3, 2025 | marketbeat.com

Precigen Announces Key Approvals at Annual Meeting

July 2, 2025 | theglobeandmail.com

Precigen (NASDAQ:PGEN) Stock Passes Above 50-Day Moving Average - Should You Sell?

June 24, 2025 | marketbeat.com

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions

June 12, 2025 | finance.yahoo.com

J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)

May 20, 2025 | theglobeandmail.com

Precigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 17, 2025 | finanznachrichten.de

Cantor Fitzgerald maintains Overweight on Precigen stock

May 17, 2025 | uk.investing.com

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025 | prnewswire.com

Is Precigen (PGEN) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Precigen options imply 20.1% move in share price post-earnings

March 20, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)

March 20, 2025 | markets.businessinsider.com

4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 Analysts

March 20, 2025 | benzinga.com

Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates

March 20, 2025 | finanznachrichten.de

Precigen Reports Progress and Financial Results for 2024

March 19, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, BLTE, IDYA, and HRMY Company Descriptions

Belite Bio NASDAQ:BLTE

$62.70 +0.67 (+1.07%)

As of 07/11/2025 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Harmony Biosciences NASDAQ:HRMY

$34.00 -0.33 (-0.96%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$34.26 +0.26 (+0.76%)

As of 07/11/2025 07:42 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

IDEAYA Biosciences NASDAQ:IDYA

$22.48 -0.32 (-1.40%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$22.46 -0.02 (-0.09%)

As of 07/11/2025 04:20 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Precigen NASDAQ:PGEN

$1.83 -0.08 (-4.19%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.82 -0.01 (-0.27%)

As of 07/11/2025 07:58 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time